Tiecheng “Alex” Qiao is the co-Founder, President & CEO of Ablaze Pharma. Dr. Qiao has over 20 years of experience as an entrepreneur, business leader and technology innovator in the life sciences, biopharmaceutical and high-tech industries.

Prior to Ablaze Pharma, he helped the acquisition of Ambrx led by Fosun Pharma, Hopu, Wuxi and Everbright, and was appointed CEO of the Company upon the completion of the acquisition. During his tenure at Ambrx, he re-built the management team and guided the Company to become a clinical stage biopharmaceutical company with a focus on developing first-in-class and best-in-class antibody drug conjugates to treat cancer.  Prior to Ambrx, he co-founded and was CEO of NajingTech from 2008 to 2012. NajingTech is an innovative materials Company focused on Quantum Dots based product development and commercialization with operations in both U.S. and China.  Prior to NajingTech, Dr. Qiao co-founded and was president of G3 Technology Innovations, which developed nanomaterials for the contract textile industry from 2006 to 2009.  G3 was acquired by private firm BigSky in 2009. Prior to his entrepreneurial career, Dr. Qiao worked at Eastman Kodak Company's Health Group (now Carestream Health) from 1997 to 2006, where he conceived and led the development of biochips, rare cell separation, and molecular imaging platforms.  

A prolific inventor with 27 issued U.S. patents, Dr. Qiao earned his Ph.D. in chemistry from the University of Rochester and completed his postdoctoral training in biochemistry at the Massachusetts Institute of Technology.  

Alan Xu is the co-Founder and COO of Ablaze Pharma. Mr. Xu has more than 25 years of combined experience in investment, business operation, business development, corporate development, finance, and supply chain management.

Prior to Ablaze Pharma, he was Executive Director of CMH Healthcare Fund, a co-GP fund of HOPU Investment, Mitsui and China Resources and he was Senior Advisor of HOPU Investments since 2018, helped fundraising for HOPU Healthcare Funds and HOPU's investment to HPGC, Lyndra, IMab and Ambrx. Prior to it, Mr. Xu was VP, GM-China and Board Secretary of Ambrx from 2015. From 2006 to 2014, he worked at China NT Pharma Group, where he had increasing management responsibilities as VP and GM of Business Development, GM of Vaccines BU, GM of Pharma Commercial. Prior to it, Mr. Xu was Head of Finance and Commercial of Dr. Reddy's China from 2003 to 2006. Previously, Mr. Xu was National Commercial and Sales Administration Manager at Bayer China from 1998 to 2003 and Associate Sales Manager of Merck Sharp & Dohme China from 1995 to 1998.

Alan received EMBA degree and BS degree in pharmaceutical from Fudan University.

Dr. Wen has more than 20 years of CMC experiences, especially in innovative drugs. Prior to Ablaze Pharma, he was the CMC Head and SVP of Pharmaceutical Sciences in Ascentage Pharma. He previously worked at Shanghai R&D Center of Wisdom Pharma as VP Director. 

Dr. Wen obtained his Ph.D in Organic Chemistry from Shanghai Institute of Organic Chemistry of CAS and completed his Postdoctoral training in the University of Tokyo. He is the author or co-author, and inventor or co-inventor, of more than 30 publications and patents.

Coco Cao is the VP of Ablaze Pharma, focusing on overall quality management.

Mrs. Cao has over 20 years of experience in pharmaceutical industry, covering drug development, quality management, materials management, procurement management and so on.

Prior to Ablaze Pharma, Mrs. Cao was the Director of Quality, Qualified Person and AVP of Quality at Ascentage Pharma from 2017 to 2022. During the 11 years in Cinkate Pharma from 2010 to 2017 and 2004 to 2009, she started from the role of Assistant Manager of Quality Management Department to Director of Quality, Qualified Person and VP of Quality and Purchasing. Prior to that, Mrs. Cao was designated as the QA Audit at Amerigen Pharma from 2009 to 2010 and Deputy Director of Pharmaceutical Formulation Department at Jiangsu Wuzhong Pharma from 2002 to 2004. Mrs. Cao is very experienced in material management, procurement management and GMP quality management of innovative drugs, from research stage to the commercialization stage. She has led projects of new GMP facility’s building-up and the establishment of quality system, as well as participations in China GMP certifications, PAI inspection for new drug and FDA inspections, with profound experience in the overall quality management of large volume parenteral solution, small volume parenteral solution, oral solution, oral solid dosage form and API.

Mrs. Cao owned 1 invention patent issued by P.R.C. and received her BS Degree in Chinese Medicine of China Pharmaceutical University.

Dr. Zheng Song is the VP of Ablaze Pharma, focusing on Pre-Clinical Development. She is a highly accomplished professional with over 16 years of experience in drug nonclinical strategy design, study conduction, and data interpretation. As a certified DABT (American Board of Toxicology) and DCST (Diplomat of Chinese Society of Toxicology), she possesses an extensive understanding of preclinical development.

Prior to joining Ablaze, Dr. Zheng Song served as Preclinical Development Head, Executive Director, at Elpiscience Biopharma, Ltd for five years. During this time, she led the preclinical development strategy design and study conduction for seven innovative antibodies to support their first-in-human clinical trials in China, the United States, and Australia. From 2007 to 2018, Dr. Zheng Song held the positions of Department Head and Project Leader at Shanghai InnoStar Bio-tech Co., Ltd. During her tenure, she led teams in completing over 60 preclinical safety evaluation projects for new candidate drugs across various therapy areas and mechanisms of action, achieving successful regulatory approvals from the FDA, NMPA, and Australia IND.

Dr. Zheng Song obtained her PhD degree from the Shanghai Institute of Pharmaceutical Industry after graduating from China Pharmaceutical University.

Susie Su is the VP of Ablaze Pharma, focusing on Clinical Science. With a background as a licensed respiratory physician, she has over 16 years of clinical development experience in chronic respiratorydiseases and solid tumors.

Prior to joining Ablaze Pharma, Susie was Executive Director of Clinical Medicine at Wuxi Biocity from 2022 to 2024, leading the team to prepare the clinical development plan for the oncology portfolio, and completing the US-China IND filing as well as the medical work for the clinical phase 1~2 studies of several molecules, including ADCs, DDRs, and immuno-oncology, etc. She worked at Elpiscience from 2020 to 2022 as the Head of Clinical Science, Senior Director, leading the team responsible for the medical and pharmacovigilance of the immuno-oncology portfolio in the clinical stage, including the preparation of clinical development plan and clinical dossier for the US-China IND filing, and the responsibility for the medical and pharmacovigilance of the clinical phase 1 studies. From 2009 to 2020, she worked for AstraZeneca China, and grew from Medical Manager to Clinical Medical Director. During the 11 years she participated in or was responsible for the late-stage clinical development in China of a number of molecules in the respiratory and lung cancer disease areas. As China Medical lead or Project Lead, she led team to undertake the late stage clinical development activities of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) and Tagrisso in Non-Small Cell Lung Cancer (NSCLC), including global simultaneous clinical development strategy, MRCT and China NDA filing.

Susie Su graduated from the Clinical Medicine Department, Medicine School of Fudan University with a Master Degree in Clinical Medicine, and worked as a respiratory physician in the Children Hospital of Fudan University from 2001 to 2007.